The popularity of Sildenafil initially sparked a surge for pharma, nevertheless recent changes present a uncertain outlook for those considering a stake. Lower-cost alternatives are eating into earnings, and ongoing legal battles add additional complexity to the equation. While some companies could still benefit from complementary products, the ove